Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × TAS-116 × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡